OmniAb, Inc.OABIEarnings & Financial Report
OmniAb, Inc. is a global biotechnology firm specializing in proprietary transgenic animal platforms and antibody discovery solutions. It partners with pharma and biotech clients to accelerate fully human therapeutic antibody development for oncology, autoimmune diseases and high-need medical areas across key global markets.
Revenue
$7.6M
Gross Profit
N/A
Operating Profit
$-16.3M
Net Profit
$-13.6M
Gross Margin
N/A
Operating Margin
-214.1%
Net Margin
-179.0%
YoY Growth
9.6%
EPS
$-0.13
OmniAb, Inc. Q2 FY2024 Financial Summary
OmniAb, Inc. reported revenue of $7.6M (up 9.6% YoY) for Q2 FY2024, with a net profit of $-13.6M (up 7.4% YoY) (-179.0% margin).
Key Financial Metrics
| Total Revenue | $7.6M |
|---|---|
| Net Profit | $-13.6M |
| Gross Margin | N/A |
| Operating Margin | -214.1% |
| Report Period | Q2 FY2024 |
Revenue Breakdown
OmniAb, Inc. Q2 FY2024 revenue of $7.6M breaks down across 3 segments, led by Services at $4.2M (54.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Services | $4.2M | 54.8% |
| License And Milestone Revenue | $3.1M | 41.0% |
| Other | $318.0K | 4.2% |
OmniAb, Inc. Revenue by Segment — Quarterly Trend
OmniAb, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Services and License And Milestone Revenue) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q4 FY2024 | Q2 FY2024 | Q4 FY2023 |
|---|---|---|---|---|
| Services | — | — | $4.2M | $2.8M |
| License And Milestone Revenue | — | — | $3.1M | $1.7M |
| Other | — | — | $318.0K | $354.0K |
OmniAb, Inc. Annual Revenue by Year
OmniAb, Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $34.2M).
| Year | Annual Revenue |
|---|---|
| 2023 | $34.2M |
| 2022 | $59.1M |
OmniAb, Inc. Quarterly Revenue & Net Profit History
OmniAb, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $8.4M | -22.5% | $-14.2M | -169.3% |
| Q4 FY2024 | $10.8M | +124.1% | $-13.1M | -121.0% |
| Q2 FY2024 | $7.6M | +9.6% | $-13.6M | -179.0% |
| Q4 FY2023 | $4.8M | -86.4% | $-14.1M | -291.4% |
| Q3 FY2023 | $5.5M | -20.7% | $-15.7M | -287.3% |
| Q2 FY2023 | $6.9M | -3.5% | $-14.7M | -212.0% |
| Q1 FY2023 | $16.9M | +75.8% | $-6.1M | -36.1% |
| Q4 FY2022 | $35.3M | — | $6.8M | 19.3% |
Income Statement
| Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q2 2024 | Q4 2024 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $35.3M | $16.9M | $6.9M | $5.5M | $4.8M | $7.6M | $10.8M | $8.4M |
| YoY Growth | N/A | 75.8% | -3.5% | -20.7% | -86.4% | 9.6% | 124.1% | -22.5% |
Balance Sheet
| Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q2 2024 | Q4 2024 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $421.2M | $413.0M | $405.2M | $391.7M | $375.2M | $337.3M | $325.6M | $300.9M |
| Liabilities | $79.8M | $72.2M | $71.4M | $67.2M | $60.6M | $43.1M | $37.9M | $33.9M |
| Equity | $341.4M | $340.8M | $333.8M | $324.5M | $314.6M | $294.2M | $287.6M | $267.0M |
Cash Flow
| Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q2 2024 | Q4 2024 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-7.1M | $27.7M | $-10.0M | $-6.2M | $-9.1M | $-12.2M | $-3.9M | $-5.7M |